Non-small cell lung carcinoma of the superior sulcus: Favourable outcomes of combined modality treatment in carefully selected patients

Clinical Prediction of Pathologic Complete Response in Superior Sulcus Non-Small Cell Lung Cancer

“…Similar findings have been reported from the Japan Clinical Oncology Group 9806 trial, with a pCR of 21% [6]. Other investigators have described pCR rates ranging from 28% to 62% [1,5,[7][8][9].…”

“…Future investigations are warranted to further predict pCR from preoperative clinical variables such as symptom resolution, as identification of accurate predictors may ultimately permit the application of selective surgical intervention in superior sulcus NSCLC. T he management of superior sulcus non-small-cell lung cancer (NSCLC) has evolved over time, with the current practice of multimodality treatment using concurrent chemoradiotherapy (CXRT) followed by surgical intervention supported by several studies [1][2][3][4][5]. The phase II Southwestern Oncology Group (SWOG) 9416 trial evaluated the role of this treatment approach in mediastinoscopy-negative patients with superior sulcus NSCLC and found it to be feasible, resulting in improved overall survival compared with historical controls.…”

Superior sulcus non-small cell lung carcinoma: A comparison of IMRT and 3D-RT dosimetry

“…11 Previous studies have shown that the rate can be improved up to 40-47% by increasing the radiation dose. 38,39 However, the benefit of this dose escalation remains to be clearly proven by controlled studies.…”

Current treatment concepts of Pancoast tumors

“…The full range of symptoms is referred to as the PancoastTobias syndrome. However, many reports classify any tumor of the apex invading the first rib as Pancoast tumors regardless of whether invasion of the brachial plexus or stellate ganglion is present or not [5][6][7][8][9][10].…”